Objective: Characteristics of preterm infants who develop pulmonary hypertension (PHT) and their response to inhaled nitric oxide (iNO) are not well described. Our objective was to identify risk factors for PHT in infants <37 weeks gestational age (GA) and to evaluate their response to iNO.
Introduction
Persistent pulmonary hypertension (PHT) of the newborn (PPHN) is a serious and sometimes fatal cardio-respiratory complication of the transition to extrauterine life. PHT occurs mainly in term infants but raised pulmonary arterial pressures (PAP) have been demonstrated in preterm infants with hyaline membrane disease by echocardiography.
1,2 PHT in preterm infants usually results from hypoxic respiratory failure secondary to significant lung pathology soon after birth, from significant pulmonary hypoplasia secondary to maternal factors such as preterm premature rupture of membranes (PPROM) and oligohydramnios or, later, from bronchopulmonary dysplasia (BPD).
Inhaled nitric oxide (iNO) has been approved for the management of PPHN in term and near-term newborns. 3, 4 However, its role in the management of hypoxic respiratory failure in preterm infants is not clear. [5] [6] [7] The beneficial effects of iNO on gas exchange, 8 pulmonary vascular disease 9 and inflammation 10 have led to its use in the prevention of BPD or in the treatment of established lung injury. 5, 7, 11 The evidence from multicenter clinical trials published to date does not support the use of iNO to decrease death or BPD in preterm infants. 5, 7 However, preliminary data from more recent large randomized trials may support a role for iNO in the prevention of BPD in established lung injury 12 and in reducing neurological injury. 13 These trials, however, were not in patients who already have documented PHT. Studying the factors predisposing to PHT and their response to iNO may help in the management of PHT in preterm infants. We studied the prenatal and postnatal characteristics of preterm infants with documented PHT in the first 4 weeks of life and their response to iNO.
Methods
We conducted a retrospective chart review of all infants <37 weeks gestation born from June/2000 to October/2005 with echocardiographic evidence of PHT in the first four weeks of life. PHT was diagnosed by the presence of tricuspid regurgitation and right to left or bidirectional shunt at the level of foramen ovale or ductus arteriosus on echocardiography. Systolic PAP were calculated based on tricuspid regurgitation jet velocity on echocardiography. To create a control group, infants within the same week of gestation as the patient born immediately before or after the patient were collected from the Neonatal intensive care unit (NICU) database. Two controls were generated for each patient with PHT matched for gestational age (GA) and closest birth date.
Echocardiography was not carried out in all control infants and, hence, we cannot state for sure that PHT did not occur in these patients. However, echocardiography is readily available in our NICU and is frequently obtained on infants with significant hypoxia or hypotension. Infants with PHT secondary to congenital heart disease were excluded from the study. Prenatal characteristics studied included antenatal steroids (any dose of steroids, including either a partial or completed course), chorioamnionitis (diagnosed in the presence of symptoms such as maternal fever, elevated white cell count or uterine tenderness or by amniotic fluid analysis for infection), oligohydramnios (defined as amniotic fluid index <5 cm by ultrasound), PPROM (rupture of membranes before 37 completed weeks of gestation and before onset of labor) and pulmonary hypoplasia (based on clinical and radiological presentation at the time of birth). Postnatal characteristics studies included GA (by first trimester fetal ultrasound or by a combination of LMP and fetal ultrasound to determine the best obstetric estimate), birth weight, Apgar score at 1 and 5 min, sex, respiratory distress syndrome (RDS), patent ductus arteriosus (PDA), sepsis (blood culture positive), systemic hypotension (defined as mean blood pressure two s.d. below the mean for that GA and postnatal age), 14 2 by univariate analysis were included in a stepwise logistic regression. One-way ANOVA was performed when comparing GA by groups. The GA related response to iNO was also analyzed by regression analysis.
Results
The mean (s.d.) pulmonary artery pressure in infants with PHT was 53.4 (±15) mm Hg. The mean (s.d.) systolic PAP to systolic systemic blood pressure ratio was 0.96 (±0.4) indicating that PHT infants had near systemic blood pressures. Sixty-one infants with PHT were compared to 122 control infants (Table 1) . Thirty-one percent (19/61 in PHT group versus 38/122 in the control group) of the preterm infants in both the groups were born weighing <1500 g. For the cohort of infants <33 weeks (all admitted to NICU during the period of this study), the incidence of PHT was 2% (24/1202). Eighty percent of infants (49/61) with PHT were diagnosed in the first week of life ( Figure 1 ). Almost all of our infants (98%; 60/61) had PHT by the end of second week of life.
Factors predisposing to pulmonary hypertension
Prenatal and postnatal characteristics that were significantly associated with PHT by univariate analysis were low Apgar score at 1 and 5 min, PPROM, oligohydramnios, chorioamnionitis, RDS, Pulmonary hypertension in preterm neonates VH Kumar et al PDA, sepsis, systemic hypotension, pulmonary hypoplasia and death (Table 1) . By stepwise logistic regression the 5 min Apgar score, PPROM, oligohydramnios, pulmonary hypoplasia and sepsis were independently predictive of PHT. PDA could not be included in the model because it was 100% predictive of PHT.
Response to nitric oxide Twenty-three (37%) of the 61 preterm infants with PHT were treated with iNO. By univariate analysis, lower GA, lower birth weight, RDS, systemic hypotension, oligohydramnios and PPROM were significantly associated with PHT in infants who received iNO compared to infants who did not receive iNO. By regression analysis PPROM was an independent predictor for iNO usage. Not surprisingly, PHT infants who received iNO were sicker with a higher O 2 requirement (93±3% versus 60±12% in infants with PHT who did not receive iNO; P<0.001) and had a higher OI (38±4 versus 9.5±5 in infants with PHT who did not receive iNO; P<0.001). Sixty-three percent (38/61) of infants were managed conservatively without nitric oxide. The response to iNO in infants with PHT across various GA groups is shown in Figure 2 . Of all infants with PHT, 54% (6/11), 60% (6/10), 37% (6/16) and 21% (5/24) of infants received iNO at 23 to 28, 29 to 31, 32 to 34 and 35 to 36 weeks, respectively. Among the infants who received iNO, 16% (1/6), 83% (5/6), 83% (5/6) and 100% (5/5) of infants responded to iNO in the respective GA groups.
In examining the prenatal and postnatal characteristics of iNO responders and non-responders (Table 2) , NO non-responders had significantly lower GA and birth weight (P<0.01). Mortality was significantly higher in the NO non-responder group (P<0.04). Arterial PO 2 increased significantly in response to iNO with increasing GA (P ¼ 0.019 by regression analysis; R 2 ¼ 0.24; Adj R 2 ¼ 0.20; Figure 3 ). Infants with lower GA were unlikely to respond: no infant <26 weeks and only 1/6 (16%) of infants <29 weeks responded to iNO. Infants >29 weeks GA responded significantly better to iNO compared to infants born <29 weeks GA (P ¼ 0.009). The response to NO increased with increasing birth weight (P ¼ 0.018; R 2 ¼ 0.24; Adj R 2 ¼ 0.20). Infants >1000 g birth weight with PHT are more likely to respond to iNO compared to infants <1000 g (P ¼ 0.001). We compared respiratory and gas exchange variables in infants who responded to NO and those who Figure 2 Response to iNO in infants with PHT across various GA groups. The stippled bars represent the percentage of infants with PHT who received iNO at various GA groups. 54% (6/11), 60% (6/10), 37% (6/16) and 21% (5/24) of infants received iNO at 23 to 28, 29 to 31, 32 to 34 and 35 to 36 weeks respectively. The dark bars represent the percentage of infants who responded to iNO out of all infants who received iNO in each GA group. Response to iNO significantly increased with GA (P<0.01, ANOVA). did not (Table 2) . By univariate analysis NO non-responders had a significantly greater number of days on MV before starting NO (1.2 day versus 6.1 days in non-responders, P<0.01).
Mortality in preterm infants with pulmonary hypertension Sixteen of the 61 (26.2%). infants with PHT died compared to five of 122 (4.1%) in the control group (P<0.0001). Comparing infants with PHT who survived versus those who died, GA, birth weight, Apgar at 1 min, male sex, sepsis, systemic hypotension and severe IVH were significantly associated with death by univariate analysis. PHT, pulmonary hypoplasia, severe IVH and lower birth weight were predictive of death in the whole study population by regression analysis. Among the infants who died, three infants (23 to 25 weeks GA) had RDS/sepsis and three infants (26 to 29 weeks GA) had PPROM-oligo-pulmonary hypoplasia sequence. Of the nine infants who died X30 weeks GA, three had congenital diaphragmatic hernia, three had dysmorphic syndromes/chromosomal anomalies and one each had bilateral renal agenesis, necrotizing enterocolitis, hydrops and neonatal encephalopathy.
Discussion
We report the clinical characteristics of preterm infants with documented PHT associated with a variety of diseases. The vast majority (98%) of PHT in the first 4 weeks occurred by the end of second week of life. Low Apgar score at 5 min, PPROM, oligohydramnios, pulmonary hypoplasia and sepsis were associated with PHT in preterm infants. Prolonged oligohydramnios attributable to premature rupture of membranes (PROM) or renal and urinary-tract malformations may lead to abnormal fetal lung development and lung hypoplasia with subsequent severe respiratory distress immediately after birth and even neonatal death. Preterm infants with hypoplastic lungs may have elevated pulmonary vascular resistance 16, 17 and this may be related to maldevelopment including a decrease in the cross-sectional area and an abnormal muscularization of the pulmonary vasculature. 18 In a large prospective cohort study of rupture of membranes (ROM) at 15 to 28 weeks' gestation, GA at the time of ROM, latency period and amniotic fluid index were important independent predictors of neonatal pulmonary hypoplasia and perinatal death. 19 Infants born with PPROM are at increased risk of respiratory distress secondary to pulmonary hypoplasia and pneumonia. [19] [20] [21] Sepsis was significantly associated with PHT in our study, and this may be related to factors such as PPROM, pneumonia and infection leading to preterm birth.
Infants with PHT had higher mortality compared to the control group. Oligohydramnios-pulmonary hypoplasia sequence resulting from lethal pathologies such as Congenital diaphragmatic hernia and renal anomalies increases perinatal mortality. Infants not responding to iNO had significantly lower birth weight and higher mortality. Broth et al. 22 used the hyperoxygenation test for pulmonary artery reactivity to predict which fetuses would be at risk for lethal pulmonary hypoplasia. A nonreactive hyperoxygenation test (defined as <20% decrease in pulsatility index of either branch pulmonary artery) predicted 79% of deaths caused by pulmonary hypoplasia. In the whole study population not only lower birth weight and severe IVH, but also PHT and pulmonary hypoplasia were associated with mortality. In the cohort of preterm infants who died, the major pathologies associated with PHT appear to be dependent on GA at birth. Although inhaled iNO improves arterial oxygenation and reduces the rate of extracorporeal membrane oxygenation in term neonates with PPHN, 3, 4 the efficacy of this therapy for acute hypoxemia owing to PHT in extremely premature infants is not clear. Our unit does not have a standard protocol regarding the use of iNO in preterm infants. At the discretion of the clinical team iNO therapy was used in extremely ill preterm infants with PHT who were not responding to maximal conventional therapy. Infants who received iNO were generally on >90% oxygen and on a mean airway pressure of >13 cm H 2 O by high frequency ventilation, although six infants with these settings did not receive iNO. In our study, 65% (15/23) of preterm infants with PHT responded to iNO. This rate is similar to that described in preterm infants <34 weeks with severe respiratory failure in the National Institute for Child Health and Human Development trial (57%). 7 However, the response to NO improved significantly with increasing GA. Infants born X29 weeks GA had a significantly greater response in terms of change in PaO 2 following iNO compared to infants <29 weeks GA. Even though we have shown that a relationship exists between iNO response and GA and birth weight, other factors may also explain the variability in response to iNO as indicated by a low r-value. The presence of documented sepsis, lower GA and lower birth weight makes response to iNO less likely. Even though duration of MV before iNO was higher in iNO non-responders compared to responders by univariate analysis, it was not significant after regression analysis when other factors were included. Prolonged MV reduces soluble guanylate cyclase in pulmonary arteries in preterm lambs and a similar phenomenon may occur in preterm infants. 23 It is probable that the physiologic immaturity of the NO signaling pathway and the anatomic immaturity of the vascular smooth muscle are responsible for the lack of response to iNO. The response of preterm infants to iNO parallels the vasodilatory response of pulmonary circulation of fetal lambs to a rise in oxygen tension. The pulmonary vasodilator response to oxygen (mediated by NO) improves with advancing GA in animal studies. [24] [25] [26] Reactivity of the human fetal pulmonary circulation to maternal hyperoxygenation also increases with advancing gestation. 27 Our data support the experimental evidence that the iNO signaling pathways may be intact in near term lambs and infants, but not in the very preterm.
The beneficial effects of iNO on gas exchange, pulmonary vascular disease and inflammation has resulted in studies addressing the efficacy of iNO in premature infants (1) to improve oxygenation in acute hypoxic respiratory failure; or (2) as prophylaxis in the prevention of BPD. A recent Cochrane review concludes that currently published evidence from randomized controlled trials does not support the use of iNO in preterm infants with respiratory failure. 28 The studies of chronic iNO exposure to prevent BPD are complicated by differences in timing and dosing; however, it is interesting to note that two of the larger studies suggest a benefit specifically in infants with birth weights of 1000 to 1250 g. 7, 13 These results are similar to pulmonary vascular responses in our population of infants, wherein infants <29 weeks GA or infants <1000 g birth weight failed to respond to iNO compared to infants X29 weeks GA or of >1000 g birth weight. Different etiologies for PHT in the lower GA groups might also have contributed to the lack of response to iNO.
The incidence of 2% of PHT in preterm infants p32 weeks GA in our study may not be the true incidence, as all infants p32 week GA did not undergo echocardiography to confirm the presence or absence of PHT. A limitation of this retrospective study is that not all infants in the control group had echocardiography to confirm the absence of PHT in this population. Although we cannot state that PHT did not occur in controls as they did not all have an echo, even if present, the PHT would be too mild or clinically insignificant because they did not warrant any therapy.
In conclusion, we present the prenatal and postnatal characteristics of premature infants with PHT and their response to iNO. Low Apgar score at 5 min, PPROM, oligohydramnios, pulmonary hypoplasia and sepsis were associated with PHT in premature infants. PHT is an independent predictor of mortality in preterm infants. Preterm infants (<29 weeks GA) are generally refractory to iNO, whereas infants X29 weeks gestation or >1000 g birth weight seemed to respond better to iNO. This information may be useful in the understanding and management of documented PHT in preterm infants.
